Sunday - May 24, 2026
Boehringer Ingelheim Licenses Preclinical Antibody Program From Immunitas Therapeutics to Advance Treatments for Chronic Inflammatory Diseases
May 13, 2026
INGELHEIM AM RHEIN, Germany, May 13 -- Boehringer Ingelheim, a pharmaceutical company, issued the following news release on May 12, 2026:

* * *

Boehringer Ingelheim licenses preclinical antibody program from Immunitas Therapeutics to advance treatments for chronic inflammatory diseases

* The first in class antibody program is designed to selectively target pathogenic cells, with the potential to deliver deeper and more durable disease control than current t . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products